Data resource basics
====================

Scope
-----

The Systemic Anti-Cancer Therapy (SACT) database is a population-based resource of SACT activity reported routinely by National Health Service (NHS) trusts in England. Data are collected on the SACT treatments of adult and paediatric patients, delivered in secondary and tertiary settings with the intention of improving survival, delaying further cancer progression or development and improving disease-free or progression-free survival. As a guide, the types of treatment NHS trusts are required to submit are listed in [Box 1](#BOX1){ref-type="boxed-text"}. Treatments such as bisphosphonates and steroids should only be submitted to SACT when they are given with disease-modifying intent (e.g. to control cancer by killing cancer cells and preventing, reducing or delaying cancer growth, development and metastasis), although there is no check on such submissions and some trusts may submit all supportive medications without qualification. It is not within the scope of the SACT database to collect treatments when prescribed as supportive therapies (e.g. to improve symptom control, quality of life or to help manage the side effects of SACT). If a treatment is submitted which would only ever be used with supportive intent, we advise that the treatment is excluded from any analysis. If a treatment is submitted which can be used with supportive or disease-modifying intent, we would assume it is being used in line with the treatment intent ([Table 1](#dyz137-T1){ref-type="table"}, field: Drug treatment intent) of the associated regimen. However, we advise analysts that there may be a data quality issue, and recommend that exclusion rules are developed on a case-by-case basis by consideration of the specific treatment and disease indication.

### Box 1. Examples of systemic anti-cancer therapies that are required and allowed to be submitted to the SACT database. (This is not an exhaustive list)

  -------------------------------------------- --------------------------------------------------
  • Standard chemotherapy                      • Steroids
  • Oral chemotherapy                          • Bisphosphates
  • Immunotherapy                              • Antibiotics[^a^](#tblfn1){ref-type="table-fn"}
  • Targeted biological therapies              • Antiemetics[^a^](#tblfn1){ref-type="table-fn"}
  • Endocrine therapies                         
  • Chimeric antigen receptor T-cell therapy    
  • Transcatheter arterial chemoembolization    
  -------------------------------------------- --------------------------------------------------

These are not required submissions, but are allowed for ease of the submitting trust.

###### 

Data field descriptions and data quality for all fields collected for use in SACT database

  Data field                                                                                                          Description                                                                                                                                                                                                 Data quality issues
  ------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Patient table**                                                                                                                                                                                                                                                                                                               
  NHS number                                                                                                          The primary identifier of a person, is a unique identifier for a patient within the NHS in England and Wales                                                                                                A small number of records have default codes (0000000000 or 1111111111)
  NHS number status indicator code                                                                                    The verification status of the NHS number provided                                                                                                                                                          No known issues
  Date of birth                                                                                                       The date on which a person was born or is officially deemed to have been born                                                                                                                               A small volume of records have 01-JAN-1900 as a default date for missing values
  Gender code                                                                                                         Person\'s gender as self-declared (or inferred by observation for those unable to declare their gender)                                                                                                     A small number of gender values are unknown \<1%
  Ethnicity[^a^](#tblfn3){ref-type="table-fn"}                                                                        The 16 + 1 ethnic data categories defined in the 2001 census, consistent with the national mandatory standard for the collection and analysis of ethnicity                                                  Can be clinician- or patient-reported, which may lead to discrepancies. Some trusts submit additional ethnicity subgroups which are not part of the standard 16 + 1 categories and therefore cannot be reliably interpreted
  Recommendation: use ethnicity from other sources (cancer registry data and HES)                                                                                                                                                                                                                                                 
  **Tumour table**                                                                                                                                                                                                                                                                                                                
  Postcode                                                                                                            The code allocated by the Post Office to identify a group of postal delivery points. Postcodes may also be used to define a geographical area                                                               No known issues
  General medical practice code                                                                                       This is the code of the GP Practice that the patient is registered with                                                                                                                                     Around 12% of records have either a missing or an unknown code, with a default code of V81999, V81997 or V81998. This has improved in more recent years
  Consultant code                                                                                                     Code of consultant who initiated SACT programme                                                                                                                                                             Around 8% of records have a missing GMC[^b^](#tblfn4){ref-type="table-fn"} code
  Care professional main speciality code                                                                              Specialty code of consultant who initiated SACT programme                                                                                                                                                   Around 7% of records have either a missing or invalid main specialty code
  Organization code                                                                                                   Organization code of the organization acting as a health care provider                                                                                                                                      A very small number of records have an invalid trust code, e.g. 000, xxx, 101
  Primary diagnosis                                                                                                   Primary diagnosis (ICD) at the start of the Systemic Anti-Cancer Therapy                                                                                                                                    Information in this field is sometimes implausible. Recommendation: use ICD site code from cancer registry data
  Morphology                                                                                                          Morphology at time of decision to treat using the International Classification of Disease for Oncology version 3 (ICDO-3)                                                                                   Some trusts report general morphology codes such as '8000/3' (malignant neoplasm) or '8010/3' (carcinoma, NOS), which may limit the ability to do accurate analysis when looking for particular cancer subtypes. This field has not been verified against data held in the cancer registry data. Recommendation: use morphology from cancer registry data
  TNM stage grouping (final pretreatment)                                                                             Record the overall clinical TNM stage grouping of the tumour, derived from each T, N and M component before treatment                                                                                       Recording of this field is unreliable due to trusts reporting non-standard staging classifications, e.g. XX1, 100, 310. Recommendation: use stage from cancer registry data when analysing primary cancers
  The overall pretreatment TNM stage grouping indicates the tumour stage at the time the treatment plan was devised                                                                                                                                                                                                               
  **Regimen table**                                                                                                                                                                                                                                                                                                               
  SACT programme number[^a^](#tblfn3){ref-type="table-fn"}                                                            Programmes of chemotherapy are numbered according to their chronological order of commencement in the patient's disease management                                                                          Some inconsistencies in this field, e.g. some sequential numbers missed. Recommendation: advise caution when using this field
  Anti-cancer regimen number[^a^](#tblfn3){ref-type="table-fn"}                                                       Regimens are numbered according to their chronological order of commencement in the patient's treatment programme                                                                                           Some inconsistencies in this field, e.g. some sequential numbers missed. Recommendation: advise caution when using this field
  Drug treatment intent                                                                                               Intent of SACT regimen                                                                                                                                                                                      In some cases individual clinicians might have used slightly different definitions of curative and palliative treatment
  Regimen analysis grouping                                                                                           SACT regimen group                                                                                                                                                                                          A small proportion (\<1%) is classified as'NOT MATCHED', e.g. a new regimen that has not been mapped to a regimen analysis grouping yet
  Regimen grouping (benchmark reports)                                                                                SACT regimen group based on benchmark reports                                                                                                                                                               A small proportion (\<1%) is classified as'NOT MATCHED', e.g. a new regimen that has not been mapped to a regimen benchmark grouping yet
  Patient's height (metres)                                                                                           Height in metres at start of SACT regimen                                                                                                                                                                   Some trusts have submitted height using centimetres as there is no upper limit validation. In some instances weight has been wrongly submitted into this field. Oral agents will often not require dosing by height, so may not be recorded
  Patient's weight (kilograms)                                                                                        Weight in kg at start of SACT regimen                                                                                                                                                                       Some trusts have submitted weight using grams or stones as there is no upper limit validation (\<1%). In some instances height has been wrongly submitted into this field. Oral agents will often not require dosing by weight, so may not be recorded
  Performance status                                                                                                  Performance status at start of SACT regimen, adult or young person                                                                                                                                          Around 6% have invalid codes, e.g. -1. Valid codes for adults = 0-4. Valid codes for young person (\<16 years) = 00-11
  Comorbidity adjustment indicator                                                                                    Whether or not patient's overall physical state (other diseases and conditions) was a significant factor in deciding on regimen, or in varying the dose or treatment interval from the start of treatment   Clinicians often interpret this as whether or not the patient has a comorbidity, rather than whether or not the patient's comorbidity influenced their prescribing decision
  Decision to treat date (drug regimen)                                                                               This is the date on which the consultation between the patient and the clinician took place and a planned cancer treatment was agreed                                                                       No known issues
  Start date (drug regimen)                                                                                           This is the first administration date of the first cycle of a regimen                                                                                                                                       A small volume of records have 01-JAN-1900 as a default date for missing values
  Clinical trial indicator                                                                                            For the SACT programme number, this identifies if a patient\'s chemotherapy treatment is within a clinical trial                                                                                            This field is known to miss recognized trial regimens, thus clinical trials are under-reported. Recommendation: advise caution when using this field
  Chemo-radiation indicator[^a^](#tblfn3){ref-type="table-fn"}                                                        This field identifies regimens which are given as part of a combined treatment with radiation                                                                                                               This field is known to miss known regimens including radiotherapy, thus chemo-radiation is under-reported. Recommendation: advise caution when using this field. Use SACT in combination with the radiotherapy dataset to determine chemo-radiation treatment
  **Cycle table**                                                                                                                                                                                                                                                                                                                 
  Cycle number                                                                                                        Cycles numbered sequentially within each regimen                                                                                                                                                            Some trusts may only report the first cycle of a treatment for a number of reasons, including technical issues with accurate cycle reporting. It may also reflect that patients stopped treatment early due to toxicity, adverse events or patient choice
  Start date (cycle)                                                                                                  Date of first drug administration in each cycle                                                                                                                                                             Disproportionately high number of patients receiving first cycle only. This has improved and there were only 22% of records with only one cycle in 2017. Some trusts have submitted '01-JAN-1900'
  Patient's height (metres)                                                                                           Height in metres at start of SACT cycle                                                                                                                                                                     Some trusts have submitted height using centimetres as there is no upper limit validation. In some instances weight has been wrongly submitted into this field. Oral agents will often not require dosing by height, so may not be recorded
  Patient's weight (kilograms)                                                                                        Weight in kg at start of SACT cycle                                                                                                                                                                         Some trusts have submitted weight using grams or stones as there is no upper limit validation (\<1%). In some instances height has been wrongly submitted into this field. Oral agents will often not require dosing by weight, so may not be recorded
  Performance status                                                                                                  Performance status at start of cycle, adult or young person                                                                                                                                                 Around 5% have invalid codes, e.g. -1. Valid codes for adults = 0-4. Valid codes for young person (\<16 years) = 00-11
  Primary procedure (OPCS)[^a^](#tblfn3){ref-type="table-fn"}                                                         Procurement code for each administration                                                                                                                                                                    No known issues
  **Drug table**                                                                                                                                                                                                                                                                                                                  
  Drug analysis grouping                                                                                              The name of the systemic anti-cancer therapy drug group given to a patient during an anti-cancer drug regimen. The name is taken from British National Formulary chapter 8                                  No known issues
  Actual dose                                                                                                         Dose in mg or other applicable unit for each administration in an SACT cycle                                                                                                                                Reported units include mg, ml, moles, micromoles and mg/m^2^ In addition, for some oral agents the reported dose may be total dose per pack, per 'course' (i.e .multiple cycles) or an estimated value
  SACT drug route of administration                                                                                   The prescribed method of delivery for each administration in an SACT cycle                                                                                                                                  No known issues
  SACT administration date                                                                                            The date on which the anti-cancer drug was administered to a patient, an infusion commenced, or an oral drug initially dispensed to the patient                                                             No known issues
  Organization code (provider)                                                                                        Code of provider for each administration in a SACT cycle                                                                                                                                                    A small number of records have a missing or invalid trust code, \<2%
  Primary procedure (OPCS)[^a^](#tblfn3){ref-type="table-fn"}                                                         Delivery code for each administration                                                                                                                                                                       No known issues
  **Outcomes table**                                                                                                                                                                                                                                                                                                              
  Start date (final treatment)                                                                                        The date of the start of the final cycle of SACT treatment within a regimen                                                                                                                                 Some trusts pre-populate this field as the latest cycle of treatment that has been delivered by the date of data extraction. This may be updated in subsequent data submissions
  Recommendation: advise caution should be used when using this field                                                                                                                                                                                                                                                             
  Regimen modification indicator -- dose reduction                                                                    Identifies if a regimen was modified by reducing the dose of any anti-cancer drug administered at any point in the regimen after commencement of the regimen                                                No known issues
  Regimen modification indicator -- time delay[^a^](#tblfn3){ref-type="table-fn"}                                     Identifies if a regimen was modified by extending the time between administration dates at any point in the regimen after commencement of the regimen                                                       No known issues
  Regimen modification indicator -- stopped early[^a^](#tblfn3){ref-type="table-fn"}                                  Identifies if a regimen was modified by reducing the administration days below the number planned                                                                                                           No known issues
  Planned treatment change reason                                                                                     To record the immediate outcome of the treatment                                                                                                                                                            No known issues

OPCS, OPCS Classification of Interventions and Procedures; GMC, General Medical Council; TNM tumour, node, metastases staging classification.

These fields have been proposed to be removed by NHS Digital in the next revision of the SACT dataset (Systemic Anti-Cancer Therapy Dataset v3.0).

A code uniquely identifying a general medical practitioner.

The SACT database is collected and curated by the National Cancer Registration and Analysis Service (NCRAS) at Public Health England (PHE), which started receiving data as part of a phased implementation from April 2012. From April 2014 it became mandatory for all NHS trusts providing SACT to submit data; however, this was not achieved by all trusts until July 2014.[@dyz137-B1] SACT data ascertainment has been compared with other national databases.[@dyz137-B2]^,^[@dyz137-B3] Data quality is thought to be sufficient for most purposes from 2013, with the caveat that not all trusts were submitting data until July 2014. Between 1 April 2017 and 31 March 2018, the database recorded a total of 1 220 370 cycles for 209 922 patients. Management of the database is clinically led, and it has been designed to understand patterns in SACT prescribing, and treatment outcomes. The dataset collects information at patient and tumour level and is designed to be linked to other data sources to provide a complete picture of the cancer patient pathway.

Purpose: SACT data for use in research and clinical practice
------------------------------------------------------------

The SACT dataset design aims to: provide data to support and improve clinical decision making; assess inequalities in access to SACT; and support commissioning \[e.g. through providing evaluations for the Cancer Drugs Fund (CDF) and assessing adherence to National Institute for Health and Care Excellence (NICE) guidance\]. Summarized SACT data are routinely reported back to the NHS trusts, using an online platform available to users with an N3 connection.[@dyz137-B4] The reports available on this platform were developed based on feedback regarding what information trusts would find the most useful in supporting clinical decision making and operational delivery of services. Reports are presented at trust, regional and national levels. In addition the data can be filtered and grouped by specialty (e.g. oncology, haematology, paediatrics), patient age and tumour types.

Examples of data included in the regular trust level reportsNumber of patients receiving treatment for each tumour group.Number and proportion of regimens reported for each treatment intent and tumour group.Distribution of performance status at start of regimen by treatment intent and tumour group.Average number of adults treated by day of the week.Number of regimens, number expected to have been completed and number with outcome recorded, stratified by intent of treatment.Outcome summary for completed regimens by intent of treatment.Names of drugs administered by tumour group.

NCRAS has been commissioned by NHS England (NHSE) to provide data and analysis for the evaluation of new CDF drugs in England.[@dyz137-B5] NICE recommends drugs to enter the CDF when there is clinical uncertainty as to whether the drug should go into routine commissioning. In many circumstances uncertainty will be addressed through a randomized controlled trial (RCT), but SACT and broader cancer data provide a secondary source of information on factors including characteristics of the patient cohort receiving the drug, their overall survival and treatment duration. This information acts to confirm the generalizability of findings from RCTs, by determining if efficacy in clinical trials translates into effectiveness in routine care. In some cases, SACT is used as the primary source for evaluation where the NICE committee believe routine data are sufficient to answer areas of clinical uncertainty in the absence or with support of an RCT. As of October 2018, there were 18 drugs in the Cancer Drugs Fund where SACT and broader NCRAS data will contribute to their evaluation for routine commissioning.[@dyz137-B6] As the SACT database does not collect source of funding for systemic therapies, NHSE initially provides additional data to identify the CDF patients.

Structure
=========

The SACT data are stored as six data tables: Patient, Tumour, Regimen, Cycle, Drug detail and Outcome (see [Table 1](#dyz137-T1){ref-type="table"}). The SACT data tables have a one-to-many relationship as shown in [Figure 1](#dyz137-F1){ref-type="fig"}; i.e. a record in the patient table may link to one or many records in the tumour table. The exception is the Outcome table for which a one-to-one relationship with the Regimen table exists; i.e. each completed record in the Regimen table will have a maximum of one record in the Outcome table. Each SACT data table contains a primary key that uniquely identifies records within that table. In addition, each table (except the patient table) contains 'foreign keys' (rows in tables that uniquely define rows in other tables) which are used to link records between tables. For example, the Drug detail table will contain foreign keys to identify which patient, tumour, regimen and cycle the record corresponds to. The internal linkage of the database means that new data on prescribed SACT will automatically be linked to a patient.

![Structure of the tables within the SACT database.](dyz137f1){#dyz137-F1}

Linkage to other data
---------------------

The SACT database can be linked to other data held by NCRAS, for example the cancer registration data, Hospital Episodes Statistics (HES),[@dyz137-B7] the Radiotherapy Dataset,[@dyz137-B8] and the Routes to Diagnosis dataset[@dyz137-B9] (see [Box 2](#BOX2){ref-type="boxed-text"} for full list). Detailed information on these datasets has been published previously.[@dyz137-B10]^,^[@dyz137-B11] Linkage of these datasets allows the whole patient pathway to be assessed.

### Box 2. Datasets and tables available to link through the National Cancer Registration and Analysis Service correct at 17 December 2018^a^

  -------------------------------------------------------------------------------------------------------------------------
  **Datasets/tables held by NCRAS**
  • Cancer registration (including patient, tumour, treatment and income domain table[^b^](#tblfn6){ref-type="table-fn"})
  • Routes to diagnosis table[^b^](#tblfn6){ref-type="table-fn"}
  • Radiotherapy dataset
  • Systemic Anti-Cancer Therapy Dataset
  **Datasets/tables accessible through NCRAS**
  • Hospital Episode Statistics (including admitted care, out-patient and accident & emergency)
  • Diagnostic Imaging Data Set
  • National Cancer Waiting Times Monitoring Data
  • National Cancer Patient Experience Survey (CPES)
  • National Cancer Diagnosis Audit
  • The Quality of Life of Cancer Survivors in England
  • The Quality of Life of Colorectal Cancer Survivors in England
  • LUCADA (Lung Cancer Data Audit (2005-2013))
  -------------------------------------------------------------------------------------------------------------------------

Updated regularly and available at \[[https://www.gov.uk/government/publications/accessing-public-health-england-data\#history\]](https://www.gov.uk/government/publications/accessing-public-health-england-data#history]).

These are derived data items.

Ascertainment of SACT
---------------------

[Table 2](#dyz137-T2){ref-type="table"} presents the number of patients treated with a SACT treatment by primary diagnosis, who appear in the SACT dataset compared with the HES-admitted patient care and outpatient care datasets. Overall the ascertainment in SACT is higher compared with HES, especially in adults. In childhood, teenage and young adult (CTYA) patients, HES has higher ascertainment for some sites, particularly in brain/central nervous system (CNS), urology and sarcoma sites. In comparison with adult cancers, CTYA tumours have different approaches to classifying diseases and less extensive roll-out of electronic prescribing systems and associated regimen mapping procedures, as well as complex multicentre models for delivering care. These all contribute to poorer ascertainment of SACT in these cancers. HES inpatient and outpatient data were used in these analyses but, due to the incomplete recording of outpatient procedures, they are likely to underestimate any treatments delivered in an outpatient setting. Only site-specific cancers were included due to a high number of secondary malignant neoplasms captured in HES (C77 -- C79) that fell into an 'other' category. This may be because hospital coding teams are attempting to code the metastases as the site of treatment, as opposed to SACT where all treatments are linked to the primary diagnosis at the start of a patient's treatment.

###### 

Number of patients captured in the Systemic Anti-Cancer Therapies (SACT) dataset vs systemic therapies[^a^](#tblfn8){ref-type="table-fn"} in HES between 1 March 2017 and 28 February 2018

                                               Adults \>=25 years   CTYA \<25 years             
  ---------------- --------------------------- -------------------- ----------------- --------- ------
  Brain/CNS        C47, C69-C72                1572                 3416              504       447
  Breast           C50                         26990                33262             30        30
  Gynaecological   C51-C58                     9350                 12035             56        58
  Head and neck    C00-C14, C30-C32            3195                 3616              35        19
  Leukaemia        C91-C95, C962, C964, C968   6473                 12051             1709      1721
  Lower GI         C18-C21                     16371                22852             35        31
  Lung             C33-C34, C37-C39, C45       16132                19571             33        18
  Lymphoma         C81-C86, C913-C914, C919    14936                16085             701       716
  Myeloma          C90                         7898                 11033             \<6^c^    --
  Sarcoma          C40-C31, C46, C49           722                  1369              406       443
  Skin             C43-C44                     1682                 3678              6         13
  Upper GI         C15-C17, C22-C25            11899                14670             52        44
  Urology          C60-C68                     12054                21882             311       279
  Total                                        129274               175520            3877^b^   3819

CTYA, childhood, teenage and young adult; CNS, central nervous system; GI, gastrointestinal.

Systemic therapy in HES defined using OPCS4 codes: X71, X72, X73, X748, X749, X352, X373, X384.  ^b^Total excluding Myeloma- due to small numbers.  ^c^non-zero number under 6.

Data collected
==============

Data submission
---------------

SACT data are recorded on hospital electronic prescribing systems. Patient details and the treatment prescribed are entered during the course of care by clinicians, nurses, pharmacists and other health care providers. There are several electronic prescribing software providers, but all produce a SACT extract in a standard format. Trusts make a data extract monthly according to their submission schedule. The few trusts without electronic prescribing use Patient Administration Systems or a manual system to produce their extracts. SACT data extracts are manually uploaded to a secure portal maintained by PHE (there is no direct interface between the portal and electronic prescribing system). Each trust has at least one registered uploader who is responsible for uploading the extract.

If there are any validation errors on the extract, for example missing data in key fields, the uploader must correct these and re-upload the data. Support with errors and the upload process is provided by the SACT helpdesk. A summary report of total administrations, new cycles and regimens is provided on the portal to enable trust users to check the data before submitting the extract.

Clinical and patient data
-------------------------

[Table 1](#dyz137-T1){ref-type="table"} provides complete information on the 43 data fields and their description, as well as any data quality issues associated with these. [Table 3](#dyz137-T3){ref-type="table"} provides information on the completeness of each data field by cancer type for the period 1 April 2017 to 31 March 2018. Data completeness has improved over the past years and, as such, cohorts including historical data will not have such complete data.

###### 

Data field completeness by cancer type for the period 1 April 2017 to 31 March 2018, the ICD-10 codes for the groups are consistent with [Table 2](#dyz137-T2){ref-type="table"}

  Diagnostic group          Number of patients   Number of tumour records   Number of regimens   Number of cycles   Number of drug records   Number of outcome records   \% NHS number   \% Date of birth   \% Current gender   \% Ethnicity   \% Patient postcode   \% GP practice code   \% GMC code^b^   \% Consultant Specialty^b^   \% Primary diagnosis
  ------------------------ -------------------- -------------------------- -------------------- ------------------ ------------------------ --------------------------- --------------- ------------------ ------------------- -------------- --------------------- --------------------- ---------------- ---------------------------- ----------------------
  Brain/CNS                        3519                    3563                    5548               14 588                26 387                     5000                  100%              100%               100%              88%               100%                   96%                99%                    100%                      100%
  Breast                          41 165                  42 761                  77 142             297 014               606 089                    70 209                 100%              100%               100%              87%               100%                   95%                99%                    100%                      100%
  Gynaecological                  12 620                  13 117                  18 645              64 801               186 589                    17 088                 100%              100%               100%              89%               100%                   96%                99%                    100%                      100%
  Head and neck                    3570                    3601                    4907               14 264                46 877                     4476                  100%              100%               100%              84%               100%                   94%                98%                    100%                      100%
  Leukaemia                       10 756                  11 098                  16 217              50 977               119 424                    15 164                 100%              100%               100%              91%               100%                   95%                97%                    100%                      100%
  Lower GI                        23 062                  23 961                  33 835             141 250               441 456                    30 779                 100%              100%               100%              85%               100%                   94%                98%                    100%                      100%
  Lung                            19 811                  20 472                  27 872              90 065               224 699                    25 343                 100%              100%               100%              85%               100%                   95%                99%                    100%                      100%
  Lymphoma                        17 569                  18 512                  27 078              80 191               328 896                    25 068                 100%              100%               100%              90%               100%                   94%                97%                    100%                      100%
  Miscellaneous^a^                16 917                  17 551                  21 644              72 011               136 835                    19 948                 100%              100%               100%              90%               100%                   95%                96%                    100%                      100%
  Myeloma                         12 970                  13 532                  24 295              88 118               228 451                    22 735                 100%              100%               100%              93%               100%                   94%                98%                    100%                      100%
  Sarcoma                          1385                    1418                    2036                6852                 17 698                     1812                  100%              100%               100%              91%               100%                   98%                99%                    100%                      100%
  Skin                             3747                    3809                    4984               25 269                34 431                     4540                  100%              100%               100%              89%               100%                   93%                99%                    100%                      100%
  Upper GI                        14 768                  15 350                  20 488              65 713               229 747                    18 472                 100%              100%               100%              85%               100%                   95%                98%                    100%                      100%
  Urology                         26 085                  26 773                  35 353             124 912               224 722                    31 993                 100%              100%               100%              86%               100%                   95%                97%                    100%                      100%
  Paediatrics (under 16)           2801                    2927                    7348               16 259                80 219                     5472                  100%              100%               100%              92%               100%                   96%                99%                    100%                      99%
  TYA (16-23)                      1599                    1677                    3082                8267                 36 404                     2669                  100%              100%               100%              88%               100%                   98%                99%                    100%                      100%
                                                                                                                                                                                                                                                                                                                                        

  Diagnostic group          \% Morphology   \% Stage of disease at start of programme   \% Programme number   \% Regimen number   \% Treatment intent   \% Regimen name   \% Height at start of regimen   \% Weight at start of regimen   \% Performance status at start of regimen   \% Comorbidity adjustment   \% Date of decision to treat   \% Start date of regimen   \% Clinical trial   \% Chemo radiation   \% Number of cycles planned   \% Cycle number
  ------------------------ --------------- ------------------------------------------- --------------------- ------------------- --------------------- ----------------- ------------------------------- ------------------------------- ------------------------------------------- --------------------------- ------------------------------ -------------------------- ------------------- -------------------- ----------------------------- -----------------
  Brain/CNS                      67%                           30%                              97%                  89%                  99%                100%                      95%                             92%                                   81%                                 75%                          90%                          100%                    98%                 95%                       89%                    100%
  Breast                         64%                           70%                              96%                  90%                  89%                100%                      86%                             86%                                   82%                                 79%                          94%                          100%                    97%                 95%                       90%                    100%
  Gynaecological                 65%                           68%                              94%                  89%                  97%                100%                      95%                             95%                                   83%                                 77%                          96%                          100%                    98%                 95%                       93%                    100%
  Head and neck                  63%                           74%                              92%                  91%                  98%                100%                      97%                             96%                                   81%                                 74%                          91%                          100%                    94%                 90%                       95%                    100%
  Leukaemia                      56%                           19%                              97%                  93%                  93%                100%                      65%                             67%                                   67%                                 83%                          94%                          100%                    97%                 95%                       90%                    100%
  Lower GI                       59%                           73%                              94%                  91%                  97%                100%                      95%                             95%                                   84%                                 81%                          94%                          100%                    98%                 93%                       92%                    100%
  Lung                           75%                           82%                              96%                  93%                  96%                100%                      90%                             91%                                   86%                                 82%                          95%                          100%                    98%                 94%                       91%                    100%
  Lymphoma                       58%                           37%                              96%                  93%                  93%                100%                      90%                             90%                                   74%                                 83%                          94%                          100%                    97%                 95%                       93%                    100%
  Miscellaneous^a^               48%                           15%                              94%                  92%                  93%                100%                      49%                             53%                                   64%                                 82%                          94%                          100%                    97%                 93%                       89%                    100%
  Myeloma                        62%                           29%                              96%                  90%                  88%                100%                      83%                             84%                                   68%                                 85%                          95%                          100%                    98%                 95%                       89%                    100%
  Sarcoma                        55%                           38%                              92%                  85%                  97%                100%                      88%                             87%                                   83%                                 62%                          92%                          100%                    91%                 86%                       90%                    100%
  Skin                           54%                           55%                              95%                  89%                  98%                100%                      77%                             86%                                   85%                                 81%                          93%                          100%                    98%                 94%                       88%                    100%
  Upper GI                       55%                           68%                              94%                  89%                  96%                100%                      90%                             91%                                   83%                                 77%                          94%                          100%                    97%                 93%                       90%                    100%
  Urology                        59%                           62%                              94%                  92%                  94%                100%                      64%                             65%                                   75%                                 78%                          94%                          100%                    96%                 94%                       88%                    100%
  Paediatrics (under 16)         67%                           8%                               99%                  77%                  98%                100%                      31%                             92%                                   10%                                 67%                          99%                          100%                    94%                 78%                       81%                    100%
  TYA (16-23)                    60%                           31%                              93%                  84%                  96%                100%                      75%                             93%                                   66%                                 60%                          90%                          100%                    90%                 82%                       89%                    100%
                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Diagnostic Group                                     \% Weight at start of cycle   \% Performance status at start of cycle   \% OPCS procurement code   \% Drug name   \% Actual dose per administration   \% Administration route   \% Administration date   \% OPCS delivery code   \% Organization code of drug provider   \% Date of final treatment   \% Regimen modification (dose reduction)   \% Regimen modification (time delay)   \% Regimen modification (stopped early)   \% Regimen outcome summary
  --------------------------------------------------- ----------------------------- ----------------------------------------- -------------------------- -------------- ----------------------------------- ------------------------- ------------------------ ----------------------- --------------------------------------- ---------------------------- ------------------------------------------ -------------------------------------- ----------------------------------------- ----------------------------
  Brain/CNS                                                        84%                                 70%                               88%                  100%                      94%                            98%                      100%                     87%                            100%                               34%                                 86%                                      70%                                      83%                                11%
  Breast                                                           80%                                 80%                               63%                  100%                      96%                            98%                      100%                     69%                             99%                               39%                                 82%                                      75%                                      81%                                12%
  Gynaecological                                                   92%                                 80%                               82%                  100%                      97%                            99%                      100%                     84%                            100%                               39%                                 85%                                      75%                                      82%                                16%
  Head and neck                                                    95%                                 81%                               75%                  100%                      94%                            99%                      100%                     80%                             99%                               46%                                 80%                                      69%                                      82%                                21%
  Leukaemia                                                        62%                                 69%                               70%                  100%                      97%                            99%                      100%                     67%                             99%                               40%                                 85%                                      75%                                      83%                                 7%
  Lower GI                                                         94%                                 83%                               84%                  100%                      95%                            98%                      100%                     85%                             99%                               34%                                 83%                                      76%                                      81%                                15%
  Lung                                                             87%                                 82%                               71%                  100%                      95%                            98%                      100%                     81%                             99%                               36%                                 83%                                      74%                                      81%                                14%
  Lymphoma                                                         89%                                 73%                               75%                  100%                      97%                            99%                      100%                     78%                             99%                               43%                                 83%                                      73%                                      81%                                10%
  Miscellaneous[^a^](#tblfn10){ref-type="table-fn"}                56%                                 67%                               71%                  100%                      93%                            99%                      100%                     75%                             99%                               41%                                 80%                                      70%                                      78%                                 6%
  Myeloma                                                          77%                                 72%                               52%                  100%                      96%                            98%                      100%                     63%                             99%                               37%                                 85%                                      75%                                      84%                                10%
  Sarcoma                                                          87%                                 85%                               75%                  100%                      98%                           100%                      100%                     70%                            100%                               40%                                 82%                                      62%                                      86%                                10%
  Skin                                                             86%                                 82%                               55%                  100%                      96%                            98%                      100%                     59%                            100%                               26%                                 85%                                      78%                                      84%                                11%
  Upper GI                                                         88%                                 81%                               80%                  100%                      95%                            98%                      100%                     85%                             99%                               35%                                 81%                                      73%                                      79%                                14%
  Urology                                                          67%                                 75%                               56%                  100%                      96%                            98%                      100%                     68%                             99%                               37%                                 76%                                      69%                                      75%                                10%
  Paediatrics (under 16)                                           93%                                 8%                                71%                  100%                      96%                            99%                      100%                     78%                            100%                               55%                                 68%                                      64%                                      67%                                 4%
  TYA (16-23)                                                      89%                                 67%                               75%                  100%                      98%                           100%                      100%                     78%                            100%                               50%                                 79%                                      55%                                      82%                                11%
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

CNS, central nervous system; GI, gastrointestinal; TYA, teenage or young person.

Any valid ICD 10 not listed in specific group.

Code uniquely identifying a general medical practitioner.

The topography of the tumour is coded using the International Classification of Disease 10th Revision,[@dyz137-B12] and the histology is coded using the International Classification of Disease Oncology 3rd revision.[@dyz137-B13] These codes refer to the primary diagnosis of the tumour and the description of the tumour at the start of SACT treatment.

Including patient's postcode as a field means that information can be mapped to other health care geographies, to support service planning within Clinical Commissioning Groups or Cancer Alliances. In addition, the patient's postcode allows the deprivation score to be determined using quintiles of income domain at the Lower Super Output Area, enabling the investigation of inequalities in prescribing of SACT.

Data collection updates
-----------------------

A review of the dataset is currently being undertaken. Version 3.0 will be an extension to the standard, introducing new data fields, correcting existing data fields and removing some data fields to reduce the burden of data collection wherever possible. This is to update the NHS Digital Information Standard ISB 1533, to standardize the recording of systemic anti-cancer therapy treatments and outcomes through electronic systems. A phased implementation of the revised data standard will start from September 2019 with full implementation by December 2019.

Data resource use
-----------------

The SACT dataset has been used to investigate 30-day mortality following SACT for lung and breast cancer patients.[@dyz137-B14] This research provided real-world evidence on the 30-day mortality of patients receiving SACT, as well as demonstrating variation between trusts. Additionally, NCRAS have produced a methodology and process for routine feeds to trusts to highlight patients who have died within 30 days of receiving SACT, to potentially support morbidity and mortality meetings. Reviews of individual deaths have been highlighted as a way to increase the quality of care.[@dyz137-B15] NCRAS plan to develop additional outcome metrics to feedback to trusts to support the delivery of care.

Henson *et al.*[@dyz137-B16] used the SACT dataset when investigating sociodemographic variation in the use of chemotherapy and radiotherapy in patients with stage IV lung, oesophageal, stomach or pancreatic cancer. This work has been further developed into an online tool[@dyz137-B17] and workbooks presenting the data.[@dyz137-B18]^,^[@dyz137-B19] Jones *et al.*[@dyz137-B20] used the SACT dataset when investigating 30-day mortality after chemotherapy for people with small-cell lung cancer. Annual reports are published for the National Cancer Audits[@dyz137-B21]; these report on SACT activity with the overall aim to review the quality of cancer care and identify areas for improvement. A list of all published reports can be found on the SACT dataset website.[@dyz137-B24] Ongoing research projects are investigating whether age is a barrier to receiving SACT,[@dyz137-B25] and examining the relationship between SACT prescription in a palliative setting and end-of-life care.[@dyz137-B26] Health Data Insight CiC (HDI), in partnership with AstraZeneca and IQVIA, have developed a dataset (the Simulacrum) containing artificial patient-like cancer data, which imitates some of the data held by NCRAS, including the SACT dataset. More information is available on the HDI website.[@dyz137-B27] The SACT and NCRAS websites contains details on the methodologies used in our various outputs.[@dyz137-B2]^,^[@dyz137-B28]

Strengths and weaknesses
========================

Strengths
---------

### Coverage and clinical detail

The key strength of the SACT database is the detailed clinical information collected with whole population coverage for England. The completeness and population-based design of the data source minimizes selection bias and increases the external validity of findings from studies using these data.[@dyz137-B29] Following PubMed searches and through conversations with international colleagues working in the field of cancer data, we have been unable to find a data source which is comparable to the SACT database in terms of its breadth or depth. NHS Scotland also collect data on SACT prescribed to patients, which can be linked to their cancer registry data, and includes laboratory test results. However, the population of Scotland is 5.5 million compared with 55 million in England, and the population coverage of the dataset is approximately 50%; therefore, there are considerably fewer patients in the dataset. Additionally, these data are not yet being made available to external researchers. Other similar international data sources are restricted by insurance status, only cover specific provinces or states or are not dedicated resources for the collection of SACT.[@dyz137-B30]

Routine population-based databases such as SACT can be used to ascertain whether findings from RCTs generalize into 'real-world' settings. Participant groups recruited to RCTs are commonly small and unrepresentative of the broader population of cancer patients.[@dyz137-B38] There may also be differences in care between patients enrolled in an RCT compared with patients in routine NHS practice. This is particularly important when the RCT-reported efficacy of a new cancer treatment is marginal, and the real-world outcomes for patients may deviate substantially from this. Population level data also facilitate reporting on serious adverse events from these treatments, which is critical given that there is concern that RCTs underestimate treatment toxicity.[@dyz137-B41]^,^[@dyz137-B42] Routine population-level databases can also be used to complete research into rare cancers where RCTs may not be practical.

### Granularity of data collection

Data should be entered into the SACT portal each and every time SACT is prescribed, as well as the outcomes associated with treatment. Such granularity of data collection enables in-depth exploration of all the drugs prescribed to patients throughout the course of their treatment.

### Data linkage

The ability to link to a variety of routine care databases collected by the NHS (see [Box 2](#BOX2){ref-type="boxed-text"}) greatly increases the granularity in which analyses can be conducted on different patient characteristics, tumour types and care pathways. Correspondingly, this enables a vast number of research questions to be addressed, such as inequalities in access to treatments. The use of primary and foreign keys within the data tables allows all records of SACT for a cycle, regimen, tumour and patient to be linked over time. This longitudinal linkage allows long-term follow-up of patients to death; in addition to variations in prescribing practice over time.

Weaknesses
----------

Many of the data issues are a result of this being a real-world database, collected routinely at the point of care. NCRAS works with trusts to support them in uploading the data, as well as supporting their transition to electronic prescribing systems. Over time, the number of data validations which are performed on the data before submission have increased.[@dyz137-B43] In the current system, records that fail the SACT portal validation process appear as critical errors and must be corrected before the file can be submitted. Data quality is also addressed when SACT data is linked to the cancer registry dataset. If any issues are identified, the SACT team have data liaison officers who support trusts to improve the quality of the data they submit. The team also has a newsletter, a helpdesk and a 'knowledge hub' to increase engagement and knowledge sharing regarding the dataset. Nevertheless, the source data are entered in real-time through electronic prescribing systems by clinicians during busy clinics, often when the patient is present. Full and accurate information may not be readily available, and there may not be time available to search other clinical records for this information. Substantial resource, therefore, has to be invested by NCRAS in processing the data before using it for analysis.

### Ascertainment

As shown in the comparison with HES data, ascertainment is poorer for CTYA cancers. Ascertainment of SACT can be heavily linked to the trusts' use of electronic prescribing systems. For CTYA trusts and centres, the initiative to use electronic prescribing was much later than for adult services. We expect to see an improvement in ascertainment of SACT among CTYA due to the increased use of electronic prescribing systems.

For several trust-level operational reasons, ascertainment is also poorer for oral chemotherapy. One example would be that some trusts do not use electronic prescribing systems for oral drugs. Drugs which are delivered 'outside' an oncology environment (e.g. in surgical clinics or in primary care) are often poorly recorded. The most pertinent example is the use endocrine therapies in breast and prostate cancer.

### Data quality

Cycle number and programme number are sometimes missing or incorrectly submitted. It is possible to infer cycle number by using the cycle date to sequentially order the SACT prescribed; however, this field was not mandatory until June 2017. Determining whether a patient has changed programme (typically called 'line of treatment' by clinicians) can be inferred with support from clinicians based upon their knowledge of the clinical pathway. Data quality for important fields such as stage and morphology are also poor (see [Table 1](#dyz137-T1){ref-type="table"}). However, this can be supplemented by linking to cancer registry data.

When inputting data, clinicians are able to name the regimens as they wish. Each trust will have a pharmacist or data uploader who is responsible for mapping the clinician-generated regimens to a list of nationally approved regimens. Whilst this only needs to be done once (the same regimen uploaded again will be automatically mapped), it is a resource-intensive process.

Before electronic prescribing, there was a disproportionately high number of patients receiving 'first cycle only' chemotherapy. It is problematic to infer from these data which patients received only a single cycle of SACT, and then stopped treatment, or whether this is a data quality issue and the patient received multiple cycles of SACT which were not recorded.

A comprehensive list of data quality issues has been provided in [Table 1](#dyz137-T1){ref-type="table"}. As indicated, some fields can be supplemented with information from the NCRAS tables, thus overcoming these issues.

Data resource access
====================

Section 251 of the NHS Act 2006 grants PHE permission to collect information on cancer patients for health improvement and service provision purposes, without the need to seek consent. These provisions are reviewed annually by the Confidentiality Advisory Group of the Health Research Authority.[@dyz137-B44]

Applications to access potentially identifiable SACT or other NCRAS data can be made to the Office for Data Release (ODR) at PHE \[<odr@phe.gov.uk>\]. There are three stages to the ODR approval process: (i) application; (ii) assessment and approval; and (iii) access. It is strongly recommended that prospective applicants discuss their proposed project with the ODR before submission of a full application. Further details regarding ODR application processes are available online.[@dyz137-B45] The NCRAS data dictionary \[<https://www.gov.uk/government/publications/accessing-public-health-england-data>\] details data items which are available for access request, and highlights which data items are potentially identifiable and therefore not available to researchers. If linkage to other NCRAS datasets is requested, linkage will be undertaken by an NCRAS analyst before release of data.

There are no restrictions on who can apply to the ODR; however, applicants are required to demonstrate that they are compliant with UK data protection laws including the Common Law Duty of Confidentiality,[@dyz137-B46] the General Data Protection Regulation (EU) 2016/679,[@dyz137-B47] and the seven Caldicott Principles.[@dyz137-B48] Furthermore, applicants must demonstrate that their purpose for using the data is consistent with the aims of health improvement and service provision, in line with the permissions to collect the data under Section 251 of the NHS Act 2006. Depending on whether the work is deemed to be research or service evaluation, applicants will also have to demonstrate approval from a research ethics committee associated with their institution.

All requests to access these data will be charged on a project basis, to reflect the amount of work required to facilitate access to requested data. Charges will be kept as low as possible and aim to cover costs rather than produce profit. Pre-application advice is offered free of charge and aims to provide expert advice to help prospective applicants. Further details regarding costs are available online.[@dyz137-B49]

The SACT helpdesk is available at \[<SACT@phe.gov.uk>\] to help support trusts with data submission, and to receive feedback from trusts on the routine reporting. In addition, data dictionaries and user guidance are available online.[@dyz137-B1]^,^[@dyz137-B24]

Conclusion
==========

The SACT dataset is a unique resource in terms of the breadth and depth of information on systemic anti-cancer drugs prescribed to cancer patients. The key strengths are the population-based nature, high level of clinical information beyond standard cancer registration data and the ability to link to other NCRAS datasets providing the opportunity to have a complete picture of the patient pathway. Considerable resource has been invested to increase data quality; however, issues relating to ascertainment and completeness of certain fields still persist. Nevertheless, a wealth of research questions can be addressed using this dataset, which will vastly improve our knowledge of SACT prescribing practice and, variation in this, as well as the associated treatment outcomes.

Profile in a nutshellThe Systemic Anti-Cancer Therapy (SACT) dataset is an ongoing mandated collection of all SACT prescribed to cancer patients by secondary and tertiary care providers in the English National Health Service (NHS).Data are collected on patient demographics, the consultant and NHS trust where the patient is being treated, tumour characteristics, the clinical status of the patient and the SACT the patient is receiving.SACT data can be linked to several datasets held by the National Cancer Registration and Analysis Service (NCRAS) and Hospital Episode Statistics (HES) to provide a more complete picture of the patient pathway.SACT data are being used for the appraisal of the drugs funded through the Cancer Drugs Fund and for a variety of observational research purposes, including investigating 30-day mortality and inequalities in access to treatment.NCRAS routinely support provider trusts with their data submissions, focusing on improving data quality and completeness. The NHS England Medicines Optimisation Commissioning for Quality and Innovation framework has supported NHS trusts in their efforts to improve data quality for a number of key items.Understanding the clinical context to SACT prescribing is key in correctly interpreting and maximizing the value of these data.

Glossary
========

  CDF: Cancer Drugs Fund

CTYA: Childhood, teenage and young adult cancer. Defined as a cancer diagnosed when aged \<25 years

Electronic prescribing system: Sends electronic prescriptions form GP surgeries directly to pharmacies

Foreign key: A field in one table that uniquely identifies a row in another table

HES: Hospital Episodes Statistics dataset. This dataset includes patient and clinical information on hospitaladmissions and attendances

ICD-10: The International Classification for Disease version 10. This is the international standard for classifying diseases and is published by the World Health organization.

ICDO-3: The International Classification for Disease Oncology version 3. This is the international standard for classifying diseases in oncology.

PHE: Public Health England

Primary key: A field which contains a unique identifier

NCRAS: National Cancer Registration and Analysis Service. This service is part of Public Health England andis responsible for all cancer registrations in England

NHS: National Health Service

RCT: Randomized controlled trial

SACT: Systemic Anti-Cancer Therapy, includes chemotherapy, immunotherapy and biological therapies

Trust: NHS foundation trusts and acute trusts ensure hospitals provide high-quality health care. The majority of hospitals in England are now managed by NHS foundation trusts. NHS trusts are independent legal entities and have unique governance arrangements
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